Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps

MT Newswires Live06-10

Cullinan Therapeutics (CGEM) said Wednesday its experimental immune therapies showed early signs of effectiveness in treating severe autoimmune diseases and outlined plans for further clinical testing.

The company said that CLN-978, a treatment targeting B cells, led to disease remission and reduced autoantibodies in a small number of patients with rheumatoid arthritis and lupus.

Some patients showed rapid improvement after stopping other immunosuppressive drugs, it added.

Cullinan said its other drug, velinotamig, showed early evidence of kidney response and major symptom improvement in patients with lupus, with no serious immune-related side effects reported in the early data.

The company said it plans to expand testing of both drugs into larger studies and additional autoimmune conditions over the next year and into 2027.

It added more clinical data updates are expected later this year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642425922?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642425922","market":"sh","top_or_hot":-1,"title":"Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a> (CGEM) said Wednesday its experimental immune therapies showed early signs of effectiveness in treating severe autoimmune diseases and outlined plans for further clinical testing.</p><p>The company said that CLN-978, a treatment targeting B cells, led to disease remission and reduced autoantibodies in a small number of patients with rheumatoid arthritis and lupus.</p><p>Some patients showed rapid improvement after stopping other immunosuppressive drugs, it added.</p><p>Cullinan said its other drug, velinotamig, showed early evidence of kidney response and major symptom improvement in patients with lupus, with no serious immune-related side effects reported in the early data.</p><p>The company said it plans to expand testing of both drugs into larger studies and additional autoimmune conditions over the next year and into 2027.</p><p>It added more clinical data updates are expected later this year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-10 20:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a> (CGEM) said Wednesday its experimental immune therapies showed early signs of effectiveness in treating severe autoimmune diseases and outlined plans for further clinical testing.</p><p>The company said that CLN-978, a treatment targeting B cells, led to disease remission and reduced autoantibodies in a small number of patients with rheumatoid arthritis and lupus.</p><p>Some patients showed rapid improvement after stopping other immunosuppressive drugs, it added.</p><p>Cullinan said its other drug, velinotamig, showed early evidence of kidney response and major symptom improvement in patients with lupus, with no serious immune-related side effects reported in the early data.</p><p>The company said it plans to expand testing of both drugs into larger studies and additional autoimmune conditions over the next year and into 2027.</p><p>It added more clinical data updates are expected later this year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CGEM","symbol_name":"Cullinan Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642425922","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642425922","pubTimestamp":1781093521,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cullinan Therapeutics  said Wednesday its experimental immune therapies showed early signs of effectiveness in treating severe autoimmune diseases and outlined plans for further clinical testing.The company said that CLN-978, a treatment targeting B cells, led to disease remission and reduced autoantibodies in a small number of patients with rheumatoid arthritis and lupus.Some patients showed rapid improvement after stopping other immunosuppressive drugs, it added.Cullinan said its other drug, velinotamig, showed early evidence of kidney response and major symptom improvement in patients with lupus, with no serious immune-related side effects reported in the early data.The company said it plans to expand testing of both drugs into larger studies and additional autoimmune conditions over the next year and into 2027.It added more clinical data updates are expected later this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CGEM":"Cullinan Therapeutics"},"translate_title":"Cullinan Therapeutics报告早期阳性自身免疫药物数据，计划下一步试验步骤","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGEM":1.5},"content_text":"Cullinan Therapeutics (CGEM) said Wednesday its experimental immune therapies showed early signs of effectiveness in treating severe autoimmune diseases and outlined plans for further clinical testing.The company said that CLN-978, a treatment targeting B cells, led to disease remission and reduced autoantibodies in a small number of patients with rheumatoid arthritis and lupus.Some patients showed rapid improvement after stopping other immunosuppressive drugs, it added.Cullinan said its other drug, velinotamig, showed early evidence of kidney response and major symptom improvement in patients with lupus, with no serious immune-related side effects reported in the early data.The company said it plans to expand testing of both drugs into larger studies and additional autoimmune conditions over the next year and into 2027.It added more clinical data updates are expected later this year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642425922","isCrawlerRequest":true}